Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

ICER has also reiterated its position that the evidence that Leqembi (lecanemab ... incomplete understanding of the underlying molecular mechanisms that could be targeted with disease-modifying ...

Its approval succeeds both the FDA’s accelerated and traditional approvals of Eisai and Biogen’s lecanemab (also known as Leqembi), a ... providing a novel mechanism to slow the progression ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Key contributors included LEQEMBI with a 28.1 billion yen increase, Lenvima with 24.9 billion yen growth, and Dayvigo up by 9.3 billion yen. Naito emphasized significant milestones for LEQEMBI ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates.

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Eisai’s Biogen-partnered Alzheimer’s therapy Leqembi is “on track” to meet a fiscal year 2024 revenue goal of ¥42.5 billion ($279 million)—despite U.S. sales continuing to drag. In the third quarter ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai’s robust sales figures for Leqembi, which exceeded consensus estimates. The ...